Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Determination of the tumor profile and review in multidisciplinary molecular board:
The genetic and immunologic profile will be performed from the available tumor sample and
from a blood sample.
- Research of mutations/insertions/deletions for an array of predefined genes in tumor
deoxyribonucleic acid by high-throughput sequencing
- Analysis of copy number variations of genes on tumor deoxyribonucleic acid by
microarray-based comparative genomic hybridization
- Analysis of rearrangements involving the gene Anaplastic Lymphoma Kinase that can't be
detected by Next Generation Sequencing or array Comparative Genomic Hybridization
(balanced translocations) by means of fluorescent hybridization probes on tumor samples
Immunologic profile: analysis of the expression of relevant immunologic markers
Retrospective clinical data collection:
Patients' clinical data will be collected retrospectively from the patient medical record.
This study is not a treatment evaluation. Patients' follow-up and treatment will be
performed according to the center local practices or to the specificities of a clinical
trial in which the patient would have been enrolled, depending on the recommendations given
by the multidisciplinary molecular board, with the review of the tumor genetic profile.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Establish a map of genetic profiles (for the pre-identified target genes) for all types of advanced malignant tumors.
Description of the incidence rates of each detected genetic disorder among the pre-identified target genes in the global cohort and for each histological type.
3 years after first patient enrollment
Jean-Yves BLAY, MD PhD
Centre Léon Bérard
France: Agence Nationale de Sécurité du Médicament et des produits de santé